The Michael J Fox Foundation

“Mjff's board of directors have designated an executive committee with the power and authority to act on behalf of the board in between regular meetings of the full board, except that the executive committee may not amend the by-laws, fill vacancies on the board, or appoint or terminate officers. Except as previously described, there are no material differences in voting rights among members of the governing body.”

“Board member relationships: two board members are in-laws and two sets of board members are married.”

“The by-laws were amended to reflect the following: (1) designation of an executive committee with the power and authority to act on behalf of the board in between regular meetings of the full board; (2) elimination of corporation members; (3) elimination of advisory boards and committees; and (4) elimination of the vice chair as a designated officer.”

“Process for review of form 990: the executive committee of the board of directors, in association with external auditors, approves the annual irs form 990 which is then made available to the entire board before it is filed.”

“Conflict-of-interest policy monitoring: officers, directors and key employees complete a conflict-of-interest questionnaire annually. The information is reviewed by corporate officers and conflicts are reviewed with the board of directors.”

“Process for determining compensation: the executive committee of the board of directors reviews and approves compensation of officers and key employees annually.”

“Governing documents are available upon request. The conflict-of-interest policy is available upon request. The consolidated financial statements are available at www.michaeljfox.org.”

“Finding the cure for parkinson's disease takes an organization with extraordinary vision. Actor michael j. Fox established the michael j. Fox foundation for parkinson's research (the "foundation"), incorporated in delaware in 2000, after publicly disclosing in 1998 that he had been diagnosed with parkinson's disease seven years earlier, at age 29. Today, the foundation is the world's largest nonprofit funder of parkinson's research. It is dedicated to accelerating a cure and ensuring the development of improved therapies for the estimated six million people worldwide living with parkinson's disease today. The foundation pursues its goals through an aggressively funded, highly targeted research program, coupled with the active global engagement of scientists, parkinson's patients and care partners, business leaders, clinical-trial participants and donors. In addition to committing more than $2 billion in research programs through the end of december 31, 2024, the foundation has fundamentally altered the trajectory of progress toward a cure. Positioned at the global hub of parkinson's research, the foundation: (i) forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; (ii) leverages new technologies to amplify the patient voice in parkinson's research; (iii) mobilizes patients and families to increase the flow of participants into clinical trials; and (iv) coordinates community engagement efforts including patient policy advocacy, education and community building through the grassroots involvement of thousands of team fox members around the world. From its inception, the foundation has invested in high-risk, high-reward research targets - an approach that in a few short years has transformed the field of parkinson's disease research. The foundation partners with the parkinson's research community, speeding financial and intellectual resources to the scientists who are carrying out projects with the greatest promise to impact patients' lives in the near term. This includes strengthening the parkinson's drug development pipeline by pushing forward investigations of genetic and other emerging targets with the best chance of stopping or slowing parkinson's disease progression, as well as by addressing patients' unmet symptomatic needs. To date, the foundation has evaluated work on more than 600 therapeutic targets, and has supported more than 125 clinical trials.”

“Change in value of split-interest agreements 1,312,701. Refunded grants 6,372,119. Loss on uncollectible accounts -290,566.”